BiotechTube

ABT-335 + Rosuvastatin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia, Renal Insufficiency

Conditions

Dyslipidemia, Renal Insufficiency

Trial Timeline

Jan 1, 2008 → Oct 1, 2008

NCT ID
NCT00585143

About ABT-335 + Rosuvastatin

ABT-335 + Rosuvastatin is a phase 1 stage product being developed by AstraZeneca for Dyslipidemia, Renal Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00585143. Target conditions include Dyslipidemia, Renal Insufficiency.

What happened to similar drugs?

15 of 20 similar drugs in Dyslipidemia, Renal Insufficiency were approved

Approved (15) Terminated (3) Active (3)
✅Pitavastatin + PravastatinEli LillyApproved
✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
✅rosuvastatin + placebo + rosuvastatin + atorvastatinAstraZenecaApproved
✅FluvastatinNovartisApproved
✅Fluvastatin extended release, fenofibrate + Fixed combination simvastatin/ezetimibeNovartisApproved
✅FluvastatinNovartisApproved
✅Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00585143Phase 1Completed

Competing Products

20 competing products in Dyslipidemia, Renal Insufficiency

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
29
Pitavastatin + PravastatinEli LillyApproved
43
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
43
YH14755 + Metformin + RosuvastatinYuhanPhase 3
40
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
29
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
29
MevalotinDaiichi SankyoPre-clinical
26
PravastatinDaiichi SankyoPre-clinical
26
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
29
LY3885125 + PlaceboEli LillyPhase 1
21
LY3561774 + PlaceboEli LillyPhase 1
29
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
35
LY3561774 + PlaceboEli LillyPhase 2
35
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
35
EvacetrapibEli LillyPhase 1
29
PPAR alpha + placeboEli LillyPhase 2
35
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
29
AZD6615 + PlaceboAstraZenecaPhase 1
21
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
29